News: Simtuzumab

We provide the latest news and info on Simtuzumab


Pulmonary Fibrosis News

Simtuzumab (GS-6624)
Pulmonary Fibrosis News
Simtuzumab, also known as GS-6624 is a pipeline drug being developed by Gilead Sciences for the treatment of Idiopathic Pulmonary Fibrosis and related conditions like Cirrhosis developed from Non-Alcoholic Steato Hepatitis (NASH).

Published on Monday 31st of August 2015 05:50:51 AM Read more...


Pharmaxis and Synairgen to Co-Develop LOXL2 Inhibitor for IPF
Pulmonary Fibrosis News
LOXL2 is a target which is of interest not only to our IPF clinical experts in Southampton but also to large pharmaceutical companies; in 2011 Gilead Sciences acquired Arresto Biosciences for $225 million for its phase I LOXL2 targeting antibody ...

and more »

Published on Monday 31st of August 2015 05:50:51 AM Read more...


Drug Discovery & Development

What Does Orphan Drug Approval For Gilead Sciences, Inc. (GILD)'s Simtuzumab Mean?
InvestCorrectly
Gilead Sciences, Inc. (NASDAQ:GILD)'s monoclonal antibody Simtuzumab recently obtained orphan drug status as a treatment for a rare liver-related disorder – primary sclerosing cholangitis. The designation may provide Gilead increased patent protection ...
Gilead Sciences: A 'Logical' Deal That 'Fits Well'Barron's (blog)
Gilead Sciences Inc To Acquire Phenex's Liver-Disease ProgramBidness ETC
Gilead Sciences Just Received Orphan Drug Status For Liver TreatmentBenzinga

all 107 news articles »

Published on Monday 31st of August 2015 05:50:51 AM Read more...


Bidness ETC

Gilead's simtuzumab fails pancreatic cancer trial
PMLiVE
Gilead Sciences has suffered a setback after its cancer candidate simtuzumab failed to achieve a survival benefit in a pancreatic cancer trial. The phase II study of simtuzumab (GS-6624) - an inhibitor of lysyl oxidase-like-2 (LOXL2) - showed that the ...
Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously ...MarketWatch
Gilead Down on Weak Simtuzumab Data and Sovaldi NewsZacks.com
Gilead's simtuzumab fails Phase 2 trial (GILD)Seeking Alpha (registration)
StockWise Daily -Drug Discovery & Development
all 45 news articles »

Published on Monday 31st of August 2015 05:50:51 AM Read more...


Seeking Alpha

Intercept Pharmaceuticals: More Upside Awaits (ICPT)
Seeking Alpha
Gilead Sciences, Inc. (NASDAQ: GILD) has two Phase 2 clinical trials for simtuzumab for NASH, and Galectin Therapeutics, Inc. (NASDAQ: GALT), Novo Nordisk A/S (ADR) (NYSE: NVO), and Mochida Pharmaceutical Co., all have compounds in clinical trials ...

Published on Monday 31st of August 2015 05:50:51 AM Read more...


Proactive Investors Chinese

Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 ...
PR Newswire (press release)
LOXL2 is a target which is of interest not only to our IPF clinical experts in Southampton but also to large pharmaceutical companies; in 2011 Gilead Sciences acquired Arresto Biosciences for $225 million for its Phase I LOXL2 targeting antibody ...
Pharmaxis and Synairgen Collaborate on LOXL2 Inhibitor to Treat IPFPulmonary Fibrosis News

all 19 news articles »

Published on Monday 31st of August 2015 05:50:51 AM Read more...


The 2015 Calendar Of NASH Trial Catalysts IV: GENFIT And Gilead
Seeking Alpha
Gilead expects 48th-week interim readouts in H2 2015 of two Phase 2b RCTs of simtuzumab (GS-6624). Simtuzumab is an inhibitory monoclonal antibody against the L2 type of lysyl oxidase (LOX), an important enzyme family that stabilizes the extracellular ...

and more »

Published on Monday 31st of August 2015 05:50:51 AM Read more...

Our Services

Do not forget to check the lastest products and auctions related to Simtuzumab as well as our free videos and podcasts.

best Simtuzumab products current Simtuzumab auctions current Simtuzumab videos listen to Simtuzumab podcasts